Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session

RATIONALE: A substantial number of breast cancer patients with an overexpression of the human epidermal growth factor receptor 2 (HER2) have residual disease after neoadjuvant therapy or become resistant to trastuzumab. Photodynamic therapy (PDT) using nanobodies targeted to HER2 is a promising trea...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Control Release
Hlavní autoři: Deken, Marion M., Kijanka, Marta M., Hernández, Irati Beltrán, Slooter, Maxime D., de Bruijn, Henriette S., van Diest, Paul J., van Bergen en Henegouwen, Paul M.P., Lowik, Clemens W.G.M., Robinson, Dominic J., Vahrmeijer, Alexander L., Oliveira, Sabrina
Médium: Artigo
Jazyk:Inglês
Vydáno: 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7116241/
https://ncbi.nlm.nih.gov/pubmed/32330574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2020.04.030
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky